Comparative Pharmacology
Head-to-head clinical analysis: ESKALITH versus LITHOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESKALITH versus LITHOBID.
ESKALITH vs LITHOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lithium modulates neurotransmission by inhibiting inositol monophosphatase, leading to reduced phosphoinositide signaling; also inhibits glycogen synthase kinase-3 (GSK-3) and alters neuronal excitability via effects on sodium transport and neurotransmitter release.
Lithium modulates neurotransmitter receptors and second messenger systems; inhibits inositol monophosphatase, reducing phosphoinositide signaling; alters ion transport; enhances serotonin and norepinephrine reuptake; modulates G-proteins.
Lithium carbonate extended-release: 300-600 mg orally twice daily, titrated to serum levels 0.6-1.2 mEq/L. Immediate-release: 300-600 mg three times daily.
300-600 mg orally 2-3 times daily; extended-release formulation (LITHOBID) 300-450 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 18-24 hours (range 12-27 hours) in adults; may be prolonged in elderly or renal impairment. Steady-state achieved in 5-7 days.
Terminal elimination half-life: 18-36 hours (mean 24 hours) in young adults, increases with age and renal impairment. Long half-life supports once-daily dosing in sustained-release formulation.
Renal: >95% excreted unchanged in urine. Biliary/fecal: negligible (<1%).
Renal: >95% excreted unchanged in urine. Biliary/fecal: <5%.
Category C
Category C
Mood Stabilizer
Mood Stabilizer